3 unknown. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 3 | 3 | Unknown 3 |
Follow Leukemia, Lymphoblastic: new trials by email Literature Review of Leukemia, Lymphoblastic trials Research Report on Leukemia, Lymphoblastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL Chidamide, Dasatinib - Leukemia, Leukemia, Acute | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 120 | 2016-02-14 | 2022-07-01 |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Dexamethasone, vincristine, Cyclophosphamide - Leukemia, Leukemia, Acute | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 80 | 2016-02-14 | 2018-06-21 |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL Chidamide, Dexamethasone, vincristine - Leukemia, Acute, Leukemia, T Cell | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 70 | 2016-02-14 | 2018-06-12 |
Leukemia (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, T-Cell (2) · Leukemia, B-Cell (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3)
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (3) · Cyclophosphamide (2) · Cytarabine (2) · Dexamethasone (2) · Doxorubicin (2) · Etoposide (2) · Idarubicin (2) · Injections, Spinal (2) · Karyotyping (2) · Mercaptopurine (2) · Methotrexate (2) · Radiotherapy (2) · Vincristine (2) · pegaspargase (2) · Dasatinib (1)
Nanfang Hospital, Southern Medical University (3)
China (3)
Hongsheng Zhou, MD, PhD (1) · Qifa Liu, MD (1)